FDA APPROVES PLC SYSTEMS PIVOTAL TRIAL OF RENALGUARD IN
U.S.
PLC Systems Inc. (OTC Bulletin Board: PLCSF), Franklin, Mass., has
received full approval from the U.S. Food and Drug Administration (FDA)
for its U.S. pivotal trial to study the effectiveness of . . .
SIGMA-ALDRICH/D-FINITIVE CELL TO DEVELOP REGENERATIVE
TOOLS.
Sigma-Aldrich (NASDAQ:SIAL}, St. Louis, has entered into a research
collaboration program with D-Finitive Cell Technologies, Inc. This
collaboration is expected to support the development and . . .
ANGIOGENEX REVIEWS 2008 AND SETS GOALS FOR 2009.
AngioGenex, Inc. (OTC Bulletin Board: AGGX) is a New York- based
biotechnology company that leads in targeting Id genes and proteins for
the discovery and development of anti- angiogenic drugs to . . .
LILLY WITHDRAWS CYMBALTA APPLICATION AND TO RESUBMIT IN
2009.
Eli Lilly and Company (NYSE:LLY), Indianapolis, has withdrawn its
supplemental New Drug Application (sNDA) from the U.S. Food and Drug
Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the . . .
ROCKWELL MEDICAL ANNOUNCES UPDATED DSMB RESULTS.(Financial
report)
Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), Wixom, Mich., a
specialty pharma company focused on drug and device development in the
renal market, has reported that the independent Data Safety . . .
ORASURE SUBMITS ORAQUICK HCV TEST PMA TO FDA.
OraSure Technologies, Inc. (NASDAQ: OSUR), Bethlehem, Penn., has
submitted a pre-market approval ("PMA") application to the
U.S. Food and Drug Administration ("FDA") for a rapid test for
antibodies . . .
TOVAXIN REDUCES DISABILITY FOR MULTIPLE SCELEROSIS.(Clinical
report)
Opexa Therapeutics, Inc. (NASDAQ:OPXA), The Woodlands, Texas, a
company dedicated to the development of patient-specific cellular
therapies for the treatment of autoimmune diseases such as . . .
NON-BRAIN PENETRANT CB1 ANTAGONISTS CAN TREAT
DIABETES/OBESITY.
Research shows that proprietary non-brain penetrant cannabinoid
subtype 1 (CB1) receptor antagonists developed by Jenrin Discovery are
able to produce metabolically favorable effects in peripheral . . .
NIH FUNDS DISCOVERY OF NEW INFLUENZA INHIBITORS.
Integral Molecular, Inc., Philadelphia, initiates a
federally-funded program to discover new drugs to combat influenza
infection. Sponsored by the National Institute of Allergy and . . .
DISCOVERY AEROSOLIZED KL-4 SURFACTANT SELECTED FOR PHASE
2A.(Clinical report)
Discovery Laboratories, Inc. (Nasdaq:DSCO), Warrington, Pa.,
announces that its proprietary, aerosolized KL-4 surfactant has been
selected for a Phase 2a clinical trial in patients with Cystic . . .
CHELSEA PATIENT DOSING IN DROXIDOPA PHASE III.
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte,
N.C., announced that it has initiated patient dosing in Study 301, the
second of two pivotal Phase III trials designed to . . .
NOVAVAX GETS GOOD RESULTS FROM PHASE I/IIA VACCINE
STUDY.(Report)
Novavax, Inc. (NASDAQ:NVAX), Rockville, Md., has announced
favorable results from the second stage of the Phase I/IIa human
clinical trial of its pandemic influenza virus-like particle . . .
LEXICON SUCCESSFULLY COMPLETES PAHSE I STUDY OF LX1031.
Lexicon Pharmaceuticals' Drug Candidate for Irritable Bowel
Syndrome Completes Phase 1 Clinical Trial Showing Positive Results
Phase 2 Proof-of-Concept Clinical Trial in IBS Patients to . . .
DISCOVERY LABS KL-4 DATA PUBLISHED IN PEDIATRIC RESEARCH.
Discovery Laboratories, Inc. (Nasdaq:DSCO), Warrington, Pa., has
announced the publication in Pediatric Research of data from a
pre-clinical research study conducted at the Nemours Research . . .
PHARMACOPEIA EARNS MILESTONE PAYMENT FROM WYETH.
Pharmacopeia (Nasdaq:PCOP), Princeton, N.J. an innovator in the
discovery and development of novel small molecule therapeutics, has
announced that it has received a milestone payment from . . .
ANTIDEPRESSANTS/COCAINE INTERACT WITH BRAIN CELL TARGETS.
In a first, scientists from Weill Cornell Medical College and
Columbia University Medical Center have described the specifics of how
brain cells process antidepressant drugs, cocaine and . . .
APP PHARMACEUTICALS GETS APPROVALS FOR ADDITIONAL
DOSAGES.
APP Pharmaceuticals, Inc. (Nasdaq:APPX), Schaumburg, Ill., a
leading manufacturer of multi-source and branded injectable
pharmaceutical products, has received final approvals from the U.S. Food
and . . .
REGENERX COMPLETES ENROLLMENT OF PHASE IA FOR HEART DRUG.
RegeneRx Biopharmaceuticals, Bethesda, Md., (AMEX:RGN) has
completed enrollment and dosing of 40 healthy subjects for its Phase IA
clinical trial testing RGN-352, an injectable formulation of T?4 . . .
SENESCO CHOOSES VGXI TO PRODUCE FACTOR 5A PLASMID.
Senesco Technologies, Inc., (AMEX:SNT), Brunswwick, N.J., has
contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to
supply the plasmid portion of the company's combination therapy
consisting . . .
HANA BIOSCIENCES GETS U.S.ORPHAN DRUG DESIGNATION FOR
MARQIBO.
Hana Biosciences (Nasdaq:HNAB), South San Francisco, Calif., a
biopharmaceutical company focused on strengthening the foundation of
cancer care, has announced that the U.S. Food and Drug . . .
|
|